Real-world dosing of omalizumab for chronic spontaneous urticaria

Ann Allergy Asthma Immunol. 2020 Feb;124(2):211-212. doi: 10.1016/j.anai.2019.11.028. Epub 2019 Dec 2.

Authors

Amanda P McIntyre¹, Ravi K Viswanathan¹, Mark H Moss¹, Sameer K Mathur²

Affiliations

¹ Division of Allergy, Pulmonary and Critical Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
² Division of Allergy, Pulmonary and Critical Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. Electronic address: skmathur@wisc.edu.

PMID: 31805358
DOI: 10.1016/j.anai.2019.11.028

No abstract available

Publication types

Letter

MeSH terms

Anti-Allergic Agents / administration & dosage*
Chronic Urticaria / diagnosis
Chronic Urticaria / drug therapy*
Chronic Urticaria / etiology
Female
Humans
Male
Omalizumab / administration & dosage*
Treatment Outcome

Substances

Anti-Allergic Agents
Omalizumab